2-Aminoethyldiphenyl Borinate: A Multitarget Compound with Potential as a Drug Precursor

BACKGROUND

Boron is considered a trace element that induces various effects in systems of the human body. However, each boron-containing compound exerts different effects.

OBJECTIVE

To review the effects of 2-Aminoethyldiphenyl borinate (2-APB), an organoboron compound, on the human body, but also, its effects in animal models of human disease.

METHODS

In this review, the information to showcase the expansion of these reported effects through interactions with several ion channels and other receptors has been reported. These effects are relevant in the biomedical and chemical fields due to the application of the reported data in developing therapeutic tools to modulate the functions of the immune, cardiovascular, gastrointestinal and nervous systems.

RESULTS

Accordingly, 2-APB acts as a modulator of adaptive and innate immunity, including the production of cytokines and the migration of leukocytes. Additionally, reports show that 2-APB exerts effects on neurons, smooth muscle cells and cardiomyocytes, and it provides a cytoprotective effect by the modulation and attenuation of reactive oxygen species.

CONCLUSION

The molecular pharmacology of 2-APB supports both its potential to act as a drug and the desirable inclusion of its moieties in new drug development. Research evaluating its efficacy in treating pain and specific maladies, such as immune, cardiovascular, gastrointestinal and neurodegenerative disorders, is scarce but interesting.

The effects of sympathetic nerve damage on satellite glial cells in the mouse superior cervical ganglion

Neurons in sensory, sympathetic, and parasympathetic ganglia are surrounded by satellite glial cell (SGCs). There is little information on the effects of nerve damage on SGCs in autonomic ganglia. We studied the consequences of damage to sympathetic nerve terminals by 6-hydroxydopamine (6-OHDA) on SGCs in the mouse superior cervical ganglia (Sup-CG). Immunostaining revealed that at 1-30 d post-6-OHDA injection, SGCs in Sup-CG were activated, as assayed by upregulation of glial fibrillary acidic protein. Intracellular labeling showed that dye coupling between SGCs around different neurons increased 4-6-fold 1-14 d after 6-OHDA injection. Behavioral testing 1-7 d post-6-OHDA showed that withdrawal threshold to tactile stimulation of the hind paws was reduced by 65-85%, consistent with hypersensitivity. A single intraperitoneal injection of the gap junction blocker carbenoxolone restored normal tactile thresholds in 6-OHDA-treated mice, suggesting a contribution of SGC gap junctions to pain. Using calcium imaging we found that after 6-OHDA treatment responses of SGCs to ATP were increased by about 30% compared with controls, but responses to ACh were reduced by 48%. The same experiments for SGCs in trigeminal ganglia from 6-OHDA injected mice showed no difference from controls, confirming that 6-OHDA acted selectively on sympathetic nerves. However, systemic inflammation induced by lipopolysaccharide did not affect SGCs of Sup-CG, but did influence SGCs in trigeminal ganglia in the same manner as 6-OHDA did on SGCs in Sup-CG. We conclude that even though SGCs in sympathetic and sensory ganglia are morphologically similar, they are quite different functionally, particularly after damage.

Distribution of postganglionic neurons which contain dopamine β-hydroxylase, tyrosine hydroxylase, neuropeptide Y and vasoactive intestinal polypeptide in the human middle cervical ganglion

The middle cervical ganglion (MCG) has been shown to contain neurotransmitters and related substances in the cat, dog and sheep. However, little is known about their presence or distribution in the human MCG. In this study, immunohistochemistry for catecholamine-synthesizing enzymes and neuropeptides was performed on the MCG in human cadavers. In 4 samples of human cadavers, MCG swellings contained numerous postganglionic neurons. In another sample, a distinct swelling of the MCG could not be detected. However, neuronal cell bodies were present within the sympathetic nerve trunk between the superior cervical and stellate ganglia. The cell size analysis demonstrated that cell bodies of postganglionic neurons measured 94.1-1774.1 μm² (mean ± S.D. = 578.1 ± 127.7 μm²) in the MCG. Postganglionic neurons in the MCG were immunoreactive for dopamine β-hydroxylase (DBH, 92.1%), tyrosine hydroxylase (TH, 59.3%), neuropeptide Y (NPY, 71.9%) and vasoactive intestinal polypeptide (VIP, 19.3%). TH-positive neurons in the human MCG appear to be infrequent compared to the sheep MCG in a previous study. In the superior cervical (SCG) and stellate ganglia (SG), 91.0% and 94.2%, respectively, of postganglionic neurons showed DBH-immunoreactivity. A total of 83.8% and 70.4%of them contained TH-immunoreactivity in the SCG and SG. However, expression of NPY in the SG (78.2%) was more abundant than in the SCG (59.1%). Only 16.4% and 13.8% of postganglionic neurons were immunoreactive for VIP in the SCG and SG, respectively. VIP-immunoreactivity was also expressed by nerve fibers surrounding some postganglionic neurons in the MCG (8.7%), SCG (11.5%) and SG (5.9%). The present study suggests that catecholamine, NPY and VIP are neurotransmitters in the MCG, SCG and SG of the human.